Effects of ABCB1 polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy
Authors:
- Guimei GuoGGGuimei Guo
- Jinyan RenJRJinyan Ren
- Hui ZhouHZHui Zhou
- Yubin GeYubin Ge
- Yingjie GuoYGYingjie Guo
- 1 May 2011
- journal article
- Published by Elsevier in Epilepsy & Behavior
- Vol. 21 (1) , 27-30
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic StrategiesEpilepsia, 2010
- The clinical impact of pharmacogenetics on the treatment of epilepsyEpilepsia, 2009
- Several major antiepileptic drugs are substrates for human P-glycoproteinNeuropharmacology, 2008
- Association of MDR1 (C3435T) Polymorphism and Resistance to Carbamazepine in Epileptic Patients from TurkeyEuropean Neurology, 2007
- Therapeutic Drug Monitoring and Clinical Outcomes in Epileptic Egyptian Patients: A Gene Polymorphism Perspective StudyTherapeutic Drug Monitoring, 2007
- Intestinal expression of cytochrome P450 enzymes and ABC transporters and carbamazepine and phenytoin dispositionActa Neurologica Scandinavica, 2007
- Searching for polymorphisms that affect gene expression and mRNA processing: Example ABCB1 (MDR1)The AAPS Journal, 2006
- Clinical factors and ABCB1 polymorphisms in prediction of antiepileptic drug response: a prospective cohort studyThe Lancet Neurology, 2006
- Identifying Candidate Causal Variants Responsible for Altered Activity of the ABCB1 Multidrug Resistance GeneGenome Research, 2004
- P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brainNeuroReport, 2001